Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Precigen, Inc.
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Bristol Licenses Dragonfly’s IL-12 Program To Boost Immunotherapies
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.
Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- ActoBio Therapeutics, Inc.
- ActoGeniX N.V.
- Exemplar Genetics
- GenVec, Inc.
- Immunologix, Inc.
- Intrexon ActoBiotics Division
- Intrexon Corporation (XON)
- Intrexon Health
- Intrexon T1D Partners, LLC (Joint Venture)
- MediStem Inc.
- MBP Titan LLC
- Trans Ova Genetics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.